Breaking WORLD PHARMA NEWS

Blocking immune cells' path into brain limits neurodegeneration

There is no treatment available today to stop the death of brain cells in neurodegenerative diseases known as tauopathies, including Alzheimer’s disease, in which twisted clumps of a protein called tau accumulate in the brain. Cells near those clumps begin to die after tau accumulates, but growing evidence suggests that much of the damage doesn’t come from the protein directly.

Read more …

Frequent cannabis use tied to more severe epilepsy

Adults with hard-to-treat epilepsy who used cannabis most days had more than twice as many convulsive seizures per year and more rapidly became resistant to antiseizure medications compared with nonusers, according to new research from Washington University School of Medicine in St. Louis. The study appears in the journal Epilepsia.

Read more …

A new technique could accelerate the development of RNA therapies

RNA vaccines and other nucleic acid therapeutics are typically packaged within fatty molecules known as lipid nanoparticles (LNPs). MIT researchers have now come up with a way to produce these particles much more quickly, and with more precise control over their size and shape.

Read more …

The concentration of pharmaceuticals in the blood in under 10 minutes

Minutes count when a patient with a stroke arrives at the hospital emergency room. Doctors stand ready to treat, but whether the blood clot can be removed medically depends on what medication the patient is already taking. Even if a blood sample is rushed through the laboratory, results can take up to an hour to arrive.

Read more …

Can AI find drugs to fight infection?

Streptococcus pneumoniae is a bacterial pathogen that causes life-threatening infections, including pneumonia and meningitis. These infections are commonly treated with antibiotics, but antibiotics are becoming less effective against S. pneumoniae over time due to changes in the pathogen that cause drug resistance. This phenomenon, called antimicrobial resistance, is resulting in significant healthcare costs and deaths around the world.

Read more …

How interferon changes cancerous blood stem cells

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects,

Read more …

New US Medicare pricing policies could reshape global pharmaceutical markets

New US Medicare pricing policies could reshape global pharmaceutical markets, potentially driving up prices and delaying medicine launches worldwide, study suggests. A new modelling study published in The Lancet suggests that US Medicare's new 'Most-Favoured-Nation' pricing policy [1], which ties what Medicare pays for medicines to prices charged in other high-income countries,

Read more …

Pfizer advances today's cancer care and tomorrow's potential breakthroughs at ESMO

Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.

Read more …

Experimental study points to systemic sclerosis treatment

Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight.

Systemic sclerosis, also called scleroderma, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs.

Read more …

An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi

We are proud Europeans. We serve as Chairs of companies born from European science, rooted in laboratories across Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, the UK, and beyond. Our duty is to safeguard our companies’ future so that we can continue to discover and develop life-changing medicines for patients.

The pharmaceutical sector is one of our continent's great post-war achievements. Built on investment in science, world-class universities, and the determination to discover medicines that change lives.

Read more …